Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain

Journal of Drug Targeting

Volumn 17, Issue 4, 2009, Pages 278-285

  Fraternale, Alessandra ^a   Paoletti, Maria Filomena ^a   Casabianca, Anna ^a   Orlandi, Chiara ^a   Millo, Enrico ^b   Balestra, Emanuela ^c   Damonte, Gianluca ^b   Perno, Carlo Federico ^c   Magnani, Mauro ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Delivery; Erythrocytes (RBC); HIV; Macrophages; Peptide nucleic acid (PNA)

Indexed keywords

GAG PROTEIN; PEPTIDE NUCLEIC ACID; PEPTIDE NUCLEIC ACID PR2; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA CONTENT; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DRUG STABILITY; ENCAPSULATION; ERYTHROCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS REPLICATION;

ANTI-HIV AGENTS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ERYTHROCYTES; FUSION PROTEINS, GAG-POL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV CORE PROTEIN P24; HIV-1; HUMANS; MACROPHAGES; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDE NUCLEIC ACIDS; YOUNG ADULT;

EID: 70749123774     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860902737474     Document Type: Article

References (42)

1. Abes R, Arzumanov AA, Moulton HM, Abes S, Ivanova GD, Iversen PL, Gait MJ, Lebleu J. (2007). Cell-penetrating-peptide-based delivery of oligonucleotides: An overview. Biochem Soc Trans, 35(Pt 4), 775-779.
2. Agrawal L, Lu X, Jin Q, Alkhatib G. (2006). Anti-HIV therapy: Current and future directions. Curr Pharm Des, 12, 2031-2055.
3. Aquaro S, Svicher V, Schols D, Pollicita M, Antinori A, Balzarini J, Perno CF. (2006). Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J Leuk Biol, 80, 1103-1110.
4. Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A, Annese V. (2008). Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: A randomized, controlled study. Am J Gastroenterol, 103, 2509-2516.
5. Boutimah-Hamoudi F, Leforestier E, Sénamaud-Beaufort C, Nielsen PE, Giovannangeli C, Saison-Behmoaras TE. (2007). Cellular antisense activity of peptide nucleic acid (PNAs) targeted to HIV-1 polypurine tract (PPT) containing RNA. Nucleic Acids Res, 35, 3907-3917.
6. Cervasi B, Paiardini M, Serafini S, Fraternale A, Menotta M, Engram J, Lawson B, Staprans SI, Piedimonte G, Perno CF, Silvestri G, Magnani M. (2006). Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1- expressingmacrophages and delays the rebound of viremia after suspension of antiretroviral therapy. J Virol, 80, 10335-10345.
7. Chaubey B, Tripathi S, Pandey VN. (2008). Single acute-dose and repeat-doses toxicity of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice. Oligonucleotides, 18, 9-20.
8. Checroune F, Yao XJ, Gottlinger HG, Bergeron D, Cohen EA. (1995). Incorporation of Vpr into human immunodeficiency virus type 1: role of conserved regions within the P6 domain of Pr55gag. J Acquir Immune Defic Syndr Hum Retrovirol, 10, 1-7.
9. Chiarantini L, Rossi L, Fraternale A, Magnani M. (1995). Modulated red-blood-cell survival by membrane-protein clustering. Mol Cell Biochem, 144, 53-59.
10. Chiarantini L, Cerasi A, Fraternale A, Andreoni F, Scarfì S, Giovine M, Clavarino E, Magnani M. (2002). Inhibition of macrophage iNOS by selective targeting of antisense PNA. Biochemistry, 41, 8471-8477.
11. Chiarantini L, Cerasi A, Fraternale A, Millo E, Benatti U, Sparnacci K, Laus M, Balestri M, Tondelli L. (2005). Comparison of novel delivery systems for antisense peptide nucleic acids. J Control Release, 109, 24-36.
12. Chiarantini L, Cerasi A, Millo E, Sparnacci K, Laus M, Riccio M, Santi S, Ballestri M, Spaccasassi S, Tondelli L. (2006). Enhanced antisense effect of modified PNAs delivered through functional PMMA microspheres. Int J Pharm, 324, 83-91.
13. Christensen L, Fitzpatrick R, Gildea B, Petersen KH, Hansen HF, Koch T, Egholm M, Buchardt O, Nielsen PE, Coull J, Berg RH. (1995). Solid-phase synthesis of peptide nucleic acids. J Pept Sci, 1, 175-183.
14. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B. (1993). PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature, 365, 566-568.
15. Fanning GC. (2006). RNA as a target for host defense and anti-HIV drugs. Curr Drug Targets, 7, 1607-1613.
16. Fraternale A, Rossi L, Magnani M. (1996). Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes. Biochim Biophys Acta, 1291, 149-154.
17. Fraternale A, Casabianca A, Orlandi C, Cerasi A, Chiarantini L, Brandi G, Magnani M. (2002). Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model. Antiviral Res, 56, 263-272.
18. Hu J, Corey DR. (2007). Inhibiting gene expression with peptide nucleic acid (PNA)-peptide conjugates that target chromosomal DNA. Biochemistry, 46, 7581-7589.
19. Ivanova G, Arzumanov AA, Turner JJ, Reigadas S, Touhmè JJ, Brown DE, Lever AM, Gait MJ. (2006). Anti-HIV activity of steric block oligonucleotides. Ann N Y Acad Sci, 1082, 103-115.
20. Kaplan AH, Manchester M, Swanstrom R. (1994). The activity of the protease of human immunodeficiency type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J Virol, 68, 6782-6786.
21. Kulkosky J, Bray S. (2006). HAART-persistent HIV-1 latent reservoirs: Their origin, mechanisms of stability and potential strategies for eradication. Curr HIV Res, 4, 199-208.
22. Lanao JM, Briones E, Colino CI. (2007). Recent advances in delivery systems for anti-HIV-1 therapy. J Drug Target, 15, 21-37.
23. Louis JM, Ishima R, Torchia DA, Weber IT. (2007). HIV-1 protease: Structure, dynamics, and inhibition. Adv Pharmacol, 55, 261-298.
24. Magnani M, Rossi L, Brandi G, Schiavano GF, Montroni M, Piedimonte G. (1992). Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc Natl Acad Sci USA, 89, 6477-6481.
25. Magnani M, Balestra E, Fraternale A, Aquaro S, Paiardini M, Cervasi B, Casabianca A, Garaci E, Perno CF. (2003). Drugloaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression. J Leuk Biol, 74, 764-771.
26. Margolis DM, Archin NM. (2006). Attacking HIV provirus: Therapeutic strategies to disrupt persistent infection. Infect Disord Drug Targets, 6, 369-376.
27. Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice R, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB. (2007). AIDS Clinical Trials Group 328 Study Team, The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: A randomized controlled clinical trial. Arc Intern Med, 167, 597-605.
28. Murray HW. (1988). Survival of intracellular pathogens within human mononuclear phagocytes. Semin Hematol, 25, 101-111.
29. Perno CF, Bergamini A, Pesce CD, Milanese G, Capozzi M, Aquaro S, Thaisrivongs S, Tarpley WG, Zon G, D'Agostini C, Rocchi G, Garaci E, Calio R. (1993). Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J Infect Dis, 168, 1148-1156.
30. Pettit SC, Clemente JC, Jeung JA, Dunn BM, Kaplan AH. (2005). Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J Virol, 79, 10601-10607.
31. Resina S, Abes S, Turner JJ, Prevot P, Travo A, Clair P, Gait MJ, Thierry AR, Lebleu B. (2007). Lipoplex and peptide-based strategies for the delivery of steric-block oligonucleotides. Int J Pharm, 344, 96-102.
32. Rossi L, Castro M, D'Orio F, Damonte G, Serafini S, Bigi L, Panzani I, Novelli G, Dallapiccola B, Panunzi S, Di Carlo P, Bella S, Magnani M. (2004). Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol Dis, 33, 57-63.
33. Rossi L, Serafini S, Pierigè F, Antonelli A, Cerasi A, Fraternale A, Chiarantini L, Magnani M. (2005a). Erythrocyte-based drug delivery. Expert Opin Drug Deliv, 2, 311-322.
34. Rossi L, Serafini S, Antonelli A, Pierigè F, Carnevali A, Battistelli V, Malatesta M, Balestra E, Caliò R, Perno CF, Magnani M. (2005b). Macrophage depletion induced by clodronate-loaded erythrocytes. J Drug Target, 13, 99-111.
35. Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, Bortner D, Kole R. (2002). Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol, 20, 1228-1233.
36. Sei S, Yang QE, O'Neill D, Yoshimura K, Nagashima K, Mitsuya H. (2000). Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol, 74, 4621-4633.
37. Shah LK, Amiji MM. (2006). Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res, 23, 2638-2645.
38. Tan XX, Actor JK, Chen Y. (2005). Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: Proof of principle using mouse intraperitoneal infection. Antimicrob Agents Chemother, 49, 3203-3207.
39. Turner JJ, Jones S, Fabani MM, Ivanova G, Arzumanov AA, Gait MJ. (2007). RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol Dis, 38, 1-7.
40. Van Aerschot A. (2006). Oligonucleotides as antivirals: Dream or realistic perspective? Antiviral Res, 71, 307-316.
41. Vyas TK, Shah L, Amiji MM. (2006). Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv, 3, 613-628.
42. Williams SA, Greene WC. (2007). Regulation of HIV-1 latency by T-cell activation. Cytokine, 39, 63-74.